Delving into the Latest Updates on Prostate cancer vaccine(Onyvax Ltd.) with Synapse

Overview

Basic Info

Drug Type

Therapeutic vaccine

Synonyms

ONY-P, Onyvax-P, Prostate cancer vaccine

+ [2]

Target-

Mechanism

Immunostimulants

Therapeutic Areas

NeoplasmsUrogenital Diseases

Active Indication

Prostatic Cancer

Inactive Indication-

Originator Organization

Onyvax Ltd.

Active Organization

Onyvax Ltd.

National Cancer Institute

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

MeCO-dried powder (PA), obtained from the supernatant left after separation of the pH 5.4-precipitating fraction from the aqueous extract of bovine parotid gland, was extracted with HOAc.The extract had a hypocalcemic activity in rabbits, but its activity fluctuated.The HOAc extract of the Me₂CO-dried powder (PAI) obtained by incubation of a suspension of the sample PA in saline, had nearly constant activity.From the purification of PAI by DEAE-cellulose chromatog. and gel chromatog. on Sephadex G-100, a hypocalcemic protein (P-MSY) was obtained in a yield of 37 mg from 10 kg of fresh gland.The sample P-MSY was homogeneous in disc electrophoresis and electrofocusing and was effective in a dose of 0.01 mg/kg.It has almost the same activity as purified Parotin.P-MSY had a mol. weight of 66,000, isoelec. point of pH 5.60, and sugar content of 2.53%.These properties and the results of amino acid anal. suggest that P-MSY is a hypocalcemic protein differing from purified Parotin.P-MSY was also different from β-Parotin or calcitonin.

100 Deals associated with Prostate cancer vaccine(Onyvax Ltd.)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Prostatic Cancer	Phase 2	-	National Cancer Institute	-
Prostatic Cancer	Phase 2	-	Onyvax Ltd.	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO2005	Phase 2	Metastatic Prostate Carcinoma	20	ONY-P1	(yqigxwsajj) = A statistically significant sustained PSA velocity reduction was seen in 3 patients (23%) wqlvbxikqb (xtvexryunk )	-	01 Jun 2005